6 completed, 3 terminated, 2 active not recruiting, 1 approved for marketing. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Coproporphyria, Hereditary: new trials by email Literature Review of Coproporphyria, Hereditary trials Research Report on Coproporphyria, Hereditary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome Autonomic Function Testing, Genetic Testing, Urine Testing - Postural Orthostatic Tachycardia Syndrome, Acute Hepatic Porphyria | Active not recruiting | Vanderbilt University Medical Center | 70 | 2022-01-19 | 2026-09-28 | |
| Prevalence of Acute Hepatic Porphyria Dosage of Delta-aminolevulinic acid and Porphobilinogen - Acute Hepatic Porphyria | Completed | Association pour la Recherche en Medecine Interne | 150 | 2021-08-23 | 2026-01-28 | |
| ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) Acute Hepatic Porphyria | Recruiting | Alnylam Pharmaceuticals | 150 | 2021-04-26 | 2026-10-06 | |
| Colombia National Porphyria Registry Rare Diseases, Porphyrias | Unknown | Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia | 100 | 2021-04-01 | 2022-09-01 | |
| Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria Web-based Survey - Porphyrias | Completed | University of South Florida | 60 | 2019-04-03 | 2019-10-16 | |
| INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP Acute Hepatic Porphyria, Hepatic Porphyrias | Terminated | Alnylam Pharmaceuticals | 212 | 2018-05-29 | 2019-01-25 | |
| A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP) Givosiran, 5-probe cocktail - Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP) | Phase 1 | Completed | Alnylam Pharmaceuticals | 10 | 2018-04-26 | 2019-03-12 |
| ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Givosiran, Placebo - Acute Hepatic Porphyria, Acute Intermittent Porphyria | Phase 3 | Completed | Alnylam Pharmaceuticals | 94 | 2017-11-16 | 2024-04-22 |
| Panhematin for Prevention of Acute Attacks of Porphyria Hemin for injection, Placebo - Acute Intermittent Porphyria, Hereditary Coproporphyria | Phase 2 | Terminated | The University of Texas Medical Branch, Galveston | 13 | 2015-10-30 | 2026-01-30 |
| EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP) Acute Hepatic Porphyria | Completed | Alnylam Pharmaceuticals | 136 | 2014-08-01 | 2021-05-17 | |
| Acute Porphyria Biomarkers for Disease Activity Hemin - Acute Intermittent Porphyria, Hereditary Coproporphyria | Active not recruiting | The University of Texas Medical Branch, Galveston | 50 | 2014-04-28 | 2026-05-12 | |
| Clinical Diagnosis of Acute Porphyria Hereditary Coproporphyria (HCP), Acute Intermittent Porphyria (AIP) | Completed | University of California, San Francisco | 148 | 2011-12-01 | 2021-09-28 | |
| The Effect of Low Intensity Exercise on Quality of Life and Hemodynamics in Patients With Permanent Atrial Fibrillation Exercise - Atrial Fibrillation | Not applicable | Terminated | University of Texas Southwestern Medical Center | 20 | 2007-07-01 | 2019-01-16 |
| Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria Givosiran - Acute Hepatic Porphyria | Approved for marketing | Alnylam Pharmaceuticals | 2024-05-20 |
Porphyria, Acute Intermittent (8) · Porphyrias (8) · Porphyria, Variegate (7) · Atrial Fibrillation (1) · Coproporphyria (1) · Motor Activity (1) · Porphyrias, Hepatic (1) · Postural Orthostatic Tachycardia Syndrome (1) · Rare Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Digestive System Diseases (14) · Genetic Diseases, Inborn (14) · Liver Diseases (14) · Metabolic Diseases (14) · Nutritional and Metabolic Diseases (14) · Skin Diseases (14) · Skin Diseases, Genetic (14) · Skin and Connective Tissue Diseases (14) · Porphyrias, Hepatic (13) · Porphyrias (6) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Arrhythmias, Cardiac (1) · Autonomic Nervous System Diseases (1)
givosiran (3) · Hemin (2) · Exercise (1) · Genetic Testing (1) · Injections (1) · Porphobilinogen (1)
Alnylam Pharmaceuticals (6) · The University of Texas Medical Branch, Galveston (2) · Association pour la Recherche en Medecine Interne (1) · Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia (1) · University of California, San Francisco (1) · University of South Florida (1) · University of Texas Southwestern Medical Center (1) · Vanderbilt University Medical Center (1)
United States (10) · France (4) · Germany (3) · Italy (3) · Spain (3) · Sweden (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Bulgaria (2) · Finland (2) · Mexico (2) · Netherlands (2) · Poland (2)
Bruce Wang, M.D. (1) · Bruce Wang, MD (1) · Cyndya Shibao, M.D (1) · D. Montgomery Bissell, MD (1) · Herbert L. Bonkovsky, M.D. (1) · James P. Kushner, M.D. (1) · Jose A Joglar (1) · Joseph R. Bloomer, M.D. (1) · Karl E Anderson (1) · Karl E Anderson, MD (1) · Karl E. Anderson, M.D. (1) · Nader Najafian, MD (1) · Quinn Dinh, MD (1) · Robert J. Desnick, Ph.D., M.D. (1)
PMID 10037110, PMID 16943900, PMID 17709712, PMID 25483980, PMID 32521132, PMID 36028858, PMID 37479139, PMID 38044204, PMID 41388232, PMID 42833135, PMID 8423877
U54DK083909 (1)